4 assets in Primary Cutaneous Lymphoma

Therapeutic assets addressing Primary Cutaneous Lymphoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Brentuximab Vedotin Primary Cutaneous Lymphoma	M.D. Anderson Cancer Center	P2	B (57)
Atlcar.Cd30.Ccr4 Cells Primary Cutaneous Lymphoma	UNC Lineberger Comprehensive Cancer Center	P1	CC (43)
Bendamustine Primary Cutaneous Lymphoma	UNC Lineberger Comprehensive Cancer Center	P1	CC (43)
Fludarabine Primary Cutaneous Lymphoma	UNC Lineberger Comprehensive Cancer Center	P1	CC (43)